Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Contract Manufacturing Global Growth at Constant by Quarter
Contract Manufacturing Global Growth at Constant Currencies (% cc) (%)
Novartis Contract Manufacturing Global Growth at Constant: -1.0% in Q3 2026, down 37.0 pts from a year earlier.
Latest, Q3 2026
-1.0%
Period ended Sep 30, 2026
Change on a year earlier
-37.0 pts
36.0% in Q3 2025
History
16 quarters
Since Q4 2022
Sources
16
Documents cited below
Where the Q3 2026 figure comes from
“|| Contract manufacturing | 390 | 396 | – 2 | – 1”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Novartis Contract Manufacturing Global Growth at Constant (%), quarterly Q4 2022–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-contract-manufacturing-yoy-cc-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.